



64 St. James's Street 1st Floor
London, SW1A 1NF
t +1 914.921.5135
t +44 20 3206 2100
t +39 02 3057 8299
GMPassist@gabelli.com
www.gabelli.com/mergerplus

7 August 2018

Dear GMP Shareholders,

Over the past several days, the market price of Gabelli Merger Plus⁺ Trust's shares has come under pressure due a small seller coupled with a lack of bids. We understand it is an institution rebalancing their portfolio. From inception through 7 August, GMP's Net Asset Value has produced a total return of 2.6%. At the time of writing of this letter however, the shares are trading at an approximately 18% discount to NAV. August volume is low, but should improve to help price discovery. We know that more brokers are becoming registered in the shares to become more active, and the Trust is appointing Cantor Fitzgerald in London as an advisor as we continue to broaden what is already a diverse and global shareholder register.

Global M&A volume totaled approximately \$1.3 trillion during the second quarter, bringing the total activity over the first half of 2018 to \$2.5 trillion, a 61% increase over the same period last year. Cross-border deal making has had its best quarter since 2007, totaling approximately \$1 trillion in the first half and accounting for about 41% of total M&A. The continued drivers that we have shared about include tax reform, a robust economy, and strong markets. All of these dynamics are giving executives continued confidence to enter into the large transactions that we have been seeing.

M&A activity remains very strong, but spreads even on fundamentally sound deals have widened in some instances due to geopolitical trade disputes arising from the US. On 25 July, it was announced that Qualcomm would no longer pursue its offer to acquire NXP Semiconductors as the deadline for the deal passed without it receiving antitrust approval from China's State Administration for Market Regulation ("SAMR"). As background, NXP agreed to be acquired by Qualcomm for \$110 cash per share in October 2016. Under pressure from activists, the deal price was raised to \$127.50 in February 2018. Ultimately, it is our view that the merger became a victim of the US-China trade war. We owned NXP because we saw the deal as both strategically and financially compelling for Qualcomm. It would have diversified Qualcomm's revenue base and been strongly accretive to EPS. While we did not view antitrust as a risk, we underestimated the impact that Sino-US trade relations ultimately had on the fate of the deal. With NXP subsequently trading into the low \$90s, we will follow the same sale discipline that we have in past deals and exit the position opportunistically as trading activity begins to normalise. There was immediate pressure on the stock as hedge funds sold their positions, but there remain several positives that may lend support to NXP going forward. Firstly, they will receive a \$2 billion termination fee which translates to about \$5.80/share. Secondly, management held a conference call on 26 July and their general tone was upbeat. The company announced a \$5 billion buyback, or approximately 15% of the shares outstanding. Post buyback, NXP will have leverage below 1.0x EBITDA, less than it has historically had. Our fundamental technology analyst has a 2018 PMV for NXP of \$115 per share.



GABELLI
FUNDS

64 St. James's Street 1st Floor
London, SW1A 1NF
t +1 914.921.5135
t +44 20 3206 2100
t +39 02 3057 8299
GMPassist@gabelli.com
www.gabelli.com/mergerplus

We continue to believe it to be an opportune time to allocate to our merger arbitrage portfolio alongside our partner capital and expect further positive performance in the coming months as deals continue to progress toward closing independent of the broader equity and fixed income markets. We have the “dry powder” to take advantage of mark to market dislocations as they arise. Our conservative and disciplined research-driven approach positions us well to invest strategically, as we continue to focus on individual deal risk, uncorrelated to broader market volatility. Further, the Trust’s 5% quarterly dividend policy remains unchanged.

We are always available for comments and/or questions and can be reached directly at +1-914-921-5135; +44 20 3206 2100; +39 02 3057 8299 or at GMPassist@gabelli.com. Thank you for your continued support and commitment.

Sincerely,

Investor Relations
Gabelli Merger Plus⁺ Trust



GABELLI
FUNDS

64 St. James's Street 1st Floor
London, SW1A 1NF
t +1 914.921.5135
t +44 20 3206 2100
t +39 02 3057 8299
GMPassist@gabelli.com
www.gabelli.com/mergerplus

Disclaimer and Important Information - Gabelli Merger Plus⁺ Trust plc:

Past performance is not indicative of future results. There can be no guarantee that the Company will achieve its investment objective. See prospectus for further detail.

This document is not for release, publication or distribution, directly or indirectly, in whole or in part in any jurisdiction where such offer or sale would be unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on Gabelli Merger Plus⁺ Trust Plc (the "Company") or GAMCO ASSET MANAGEMENT (UK) LTD (or any of its affiliated entities) together ("GAMCO"). Persons into whose possession this document comes must inform themselves about, and observe, any such restrictions as any failure to comply with such restrictions may constitute a violation of the securities law of any such jurisdiction. This document has been prepared by the Company for information purposes only and does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for, ordinary shares of \$0.01 each in the capital of the Company ("Ordinary Shares") in any jurisdiction where such an offer or solicitation is unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on the Company or GAMCO. The offer and sale of Ordinary Shares have not been and will not be registered under the applicable securities laws of the United States, Australia, Canada, South Africa or Japan. Subject to certain exceptions, the Ordinary Shares may not be offered or sold within the United States, Australia, Canada, South Africa or Japan or to any national, resident or citizen of the United States, Australia, Canada, South Africa or Japan. This document does not constitute any form of financial opinion or recommendation on the part of the Company or any of its affiliates or advisers and is not intended to be an offer, or the solicitation of any offer, to buy or sell any securities in any jurisdiction. Each investor must comply with all legal requirements in each jurisdiction in which it purchases, offers or sells the Company's securities, and must obtain any consents, approval or permission required by it.

This document is an advertisement and not a prospectus and investors should not subscribe for or purchase any securities except on the basis of information in the prospectus to be published by the Company in due course in connection with the application to be made to the UK Listing Authority and the London Stock Exchange for the Ordinary Shares proposed to be issued to be admitted to listing on the premium listing segment of the Official List and to trading on the Main Market for listed securities of the London Stock Exchange respectively (the "Prospectus"). Copies of the Prospectus will, following publication, be available from the Company's registered office.

The Ordinary Shares have not been nor will be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and the Ordinary Shares may not be offered, sold, exercised, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the U.S. Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction in the United States. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended (the "U.S. Investment Company Act") and investors will not be entitled to the benefits of the U.S. Investment Company Act.

This document has not been approved (for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA")).

This document is being issued to and directed only at: (i) persons who have professional experience in matters relating to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order"); or (ii) persons who fall within Article 43 of the Financial Promotion Order (members and creditors of certain bodies corporate); or (iii) persons who fall within Article 49(2) of the Financial Promotion Order (including certain high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts, or other respective directors, officers or employees as described in Article 49 of the Financial Promotion Order); or (iv) any other persons to whom this presentation for the purposes of Section 21 of FSMA can otherwise lawfully be made without further action; or (v) persons otherwise permitted by the laws of the jurisdiction in which they are resident to receive them; or (vi) in relation to persons in member states of the European Economic Area ("EEA"), are a "professional client" or an "eligible counterparty" within the meaning of Article 4(1)(II) and 24(2); (3) and (4), respectively, of MiFID (as MiFID is implemented into national law of the relevant EEA state). This document is not intended to be, and must not be, distributed, passed on or disclosed, directly or indirectly, to any other class of person.

The condition of you receiving this document is that you fall within one of the categories of persons described above and by accepting this document you will be taken to have warranted, represented and undertaken to the Company that: (a) you fall within one of the categories of persons described above, (b) you have read, agree to and will comply with the terms of this disclaimer; and (c) you will conduct your own analyses or other verification of the data set out in this document and will bear the responsibility for all or any costs incurred in doing so.

Persons who do not fall within one of the categories of persons described above should not rely on this document nor take any action upon them, but should return them immediately to the Company at its registered office.

In addition, the Ordinary Shares will only be offered to the extent that the Company: (i) is permitted to be marketed into the relevant EEA jurisdiction pursuant to either Article 36 or 42 of the EU Directive on Alternative Investment Fund Managers (if and as implemented into local law); or (ii) can otherwise be lawfully offered or sold (including on the basis of an unsolicited request from a professional investor).